Vivos Therapeutics Announced That Its Daytime-nighttime Appliance Will Be Tested In A Clinical Trial At Stanford Medicine; The Protocol Has Been Finalized And Participant Enrollment Will Begin In Early 2024
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics has announced that its flagship daytime-nighttime appliance will be tested in a clinical trial at Stanford Medicine. The protocol for the trial has been finalized and participant enrollment will begin in early 2024.
October 11, 2023 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics' announcement of its clinical trial at Stanford Medicine for its flagship product could potentially boost investor confidence in the company's product pipeline.
The announcement of a clinical trial at a reputable institution like Stanford Medicine is a positive development for Vivos Therapeutics. It indicates progress in the company's product development and could potentially boost investor confidence in the company's product pipeline. However, the actual impact on the stock price will depend on the trial results, which are yet to be known.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100